Literature DB >> 15611854

Somatostatin treatment of spontaneous chylothorax in an extremely low birth weight infant.

Ryszard Lauterbach, Bozena Sczaniecka, Justyna Koziol, Marta Knapczyk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15611854     DOI： 10.1007/s00431-004-1608-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  6 in total

1.  Somatostatin in the treatment of chylothorax.

Authors:  N J Demos; J Kozel; J E Scerbo
Journal:  Chest       Date:  2001-03       Impact factor: 9.410

2.  The effectiveness of octreotide in the treatment of post-operative chylothorax.

Authors:  Luca Rosti; Roberta M Bini; Massimo Chessa; Gianfranco Butera; Manuela Drago; Mario Carminati
Journal:  Eur J Pediatr       Date:  2002-03       Impact factor: 3.183

3.  Treatment of chylothorax in a premature infant using somatostatin.

Authors:  Maki Goto; Kazuya Kawamata; Masanao Kitano; Ken Watanabe; Yosihide Chiba
Journal:  J Perinatol       Date:  2003-10       Impact factor: 2.521

4.  Spontaneous neonatal chylothorax treated with octreotide in Turkey: a case report.

Authors:  Ercan Sivasli; Deniz Dogru; Ayse Tana Aslan; Murat Yurdakok; Gulsevin Tekinalp
Journal:  J Perinatol       Date:  2004-04       Impact factor: 2.521

5.  Conservative management of postoperative chylothorax using somatostatin.

Authors:  R F Kelly; S J Shumway
Journal:  Ann Thorac Surg       Date:  2000-06       Impact factor: 4.330

6.  Somatostatin analog (octreotide) in management of neonatal postoperative chylothorax: is it safe?

Authors:  Hadi Mohseni-Bod; Duncan Macrae; Zdenek Slavik
Journal:  Pediatr Crit Care Med       Date:  2004-07       Impact factor: 3.624
  6 in total
  1 in total

Review 1.  Somatostatin or octreotide as treatment options for chylothorax in young children: a systematic review.

Authors:  Charles C Roehr; Andreas Jung; Hans Proquitté; Oliver Blankenstein; Hannes Hammer; Kokila Lakhoo; Roland R Wauer
Journal:  Intensive Care Med       Date:  2006-03-11       Impact factor: 17.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.